Invasive Ductal Carcinoma (Breast) Treatment — in Hyderabad

Surgery is the primary local treatment for invasive ductal carcinoma. In a lumpectomy (breast-conserving surgery), only the tumour and a rim of healthy tissue around it are removed, preserving the rest of the breast. This option is suitable when the tumour is small relative to the breast size and is usually followed by radiation therapy to reduce local recurrence risk.

When a mastectomy is needed — because the tumour is large, there are multiple tumour sites, or the patient chooses it — CION's surgical oncologists are trained in oncoplastic techniques that can preserve the breast shape. Reconstruction options (immediate or delayed) are discussed before surgery so you can make an informed choice without time pressure. Your surgical team will explain both options clearly at your consultation.

Chemotherapy uses medicine delivered through an intravenous drip or oral tablets to destroy cancer cells throughout the body. It can be given before surgery (neoadjuvant) to shrink the tumour and make surgery easier, or after surgery (adjuvant) to eliminate any cancer cells that may remain.

The decision to use chemotherapy, and when to use it, depends on the tumour size, lymph node status, grade, and receptor profile of your specific IDC. Not all patients with invasive ductal carcinoma need chemotherapy — your tumor board will explain clearly whether it is part of your plan and what to expect during and after each treatment cycle. CION's allied care team includes a nutritionist and psycho-oncologist to support you throughout.

Radiation therapy uses high-energy beams to destroy any cancer cells remaining in the breast or chest area after surgery. It is typically recommended after a lumpectomy and in some cases after a mastectomy (particularly when lymph nodes were involved).

Modern radiation techniques such as 3D-CRT and IMRT allow oncologists to shape the radiation beam precisely around the treatment area, minimising exposure to the heart and lungs. Treatment is usually delivered daily, Monday to Friday, over 3 to 6 weeks. CION's radiation oncologists will map your radiation plan carefully to protect surrounding healthy tissue while maximising the dose to any residual cancer cells.

If your IDC tests positive for oestrogen receptors (ER+) or progesterone receptors (PR+), hormone-blocking therapy is a key part of the duct cell carcinoma of breast treatment plan. These medicines work by reducing the amount of oestrogen in the body or blocking oestrogen from attaching to cancer cells — preventing the hormone from stimulating tumour growth.

Hormone-blocking therapy is taken orally, typically once a day, and is continued for several years after the initial treatment. The type of medicine and duration depend on whether you are pre-menopausal or post-menopausal. For patients with invasive carcinoma grade 2 that is hormone receptor-positive, this therapy significantly reduces the risk of the cancer returning. Your oncologist will explain the options and side-effect profile in detail.

If your IDC tumour overexpresses the HER2 protein (HER2-positive), targeted therapy is added to your treatment plan. Targeted therapy medicines attach specifically to the HER2 protein on cancer cells, blocking the signals that tell them to grow and divide — without affecting normal cells the way chemotherapy does.

Targeted therapy for HER2-positive IDC is typically given intravenously, initially alongside chemotherapy and then continued on its own for up to a year. This combination has significantly improved outcomes for HER2-positive invasive ductal carcinoma over the past two decades. Your medical oncologist will explain exactly how targeted therapy fits into your overall treatment plan and what to watch for during treatment.

For patients with triple-negative invasive ductal carcinoma (TNBC) — where hormone-blocking and targeted therapies do not apply — immunotherapy is an increasingly important treatment option. Immunotherapy works by helping your own immune system recognise and attack cancer cells more effectively.

Immunotherapy is typically considered when TNBC is at a certain stage or when specific biomarkers are present on the tumour. It is usually given in combination with chemotherapy. Not every patient with TNBC will be a candidate for immunotherapy — eligibility depends on tumour testing. CION's tumor board reviews each triple-negative IDC case to identify whether immunotherapy adds meaningful benefit to the individual's treatment plan before recommending it.